If you want to pump your immune system, don’t add toxins! boost your immune system!!!!!

 

We try as a culture to follow the science and do the right thing for us and those around us, more often than not the advice we are given by those in power is exactly the opposite of what we need to do. This is evident in the stock and bonds market, the housing market and no more apparent than in the health sector.

As a holistic health coach the best i can do is literally to facepalm myself as i watch countless friends and relatives make decisions that have high possibilities for consequences.

As a holistic health coach, it’s my job to give people advice that minimises the possbility of negative health consequences just as it’s the trading teachers job to give people advice to minimise their losses.

This is where probiotics come into the equation and not just any probiotics, years of research against chronic inflammatory and fungal based infections that culminated in the disappearance of somewhere in the region of 12 research scientists. This became known as the well known “dead doctors don’t lie” the video has been scrubbed.

How do you know the right things to do?

Have you ever tried the polar opposite of what mainstream media says? This is a great starting point.

What is GcMAF

Remeber these phrases in health:

“support yourself” 

“give your body what it needs and it will heal itself”

 

Your body’s own internal medicine

In a healthy person your internal GcMAF has 11 actions including; two on cells, three  on the brain, and 6 on chronic inflammation, the big C. Amongst these it acts as a “director” of your immune system.

Viruses and malignant or diseased cells send out an enzyme called Nagalase that prevents production of your own GcMAF: in effect neutralising your immune system.  Diseases the becomes chronic, and diseased cells metastasize unchecked.

Minutes after a receiving a dose of GcMAF, 10 of the actions restart.

In three weeks (of one GcMAF dose a week), your immune system is rebuilt to over peak strength.

You need one to two doses a week for typically 24 weeks for many diseases and early chronic inflammation, up to seven one ml doses a week and a year for stage 4 diseases.

The disease is then taken down without side effects, and successfully in up to 80% of cases -depending upon how well you follow the rest of your supplemental and diet plan.

Is It Backed up by Science?

GcMAF is extracted and isolated,  our GcMAF has undergone hundreds of laboratory experiments in universities, laboratories and clinics and been the subject of 25 scientific research papers.

What does GcMAF do?

The GcMAF Conference 2013 showed GcMAF is a far more powerful molecule than we thought, both in terms of the science, and doctors’ results.

In stage 4 diseases, some doctors who choose the right complimentary therapies are saving every patient. We’ve had complete successes with many common diseases including prostate, lung, breast and melanoma, and a little with blood.

The immune system can eradicate chronic inflammation, bacterial and viral infections, and our GcMAF has been successful here. Autism, Chronic Herpes, Chronic Acne, Chronic cirrhosis of the liver, Chronic kidney disease, Chronic depression, Colitis, Crohn’s, Fibromyalgia, Hepatitis, LMBBS, ME/CFS, Osteoporosis, and various types of Immune dysfunction including allergies.

Research shows GcMAF can halt deterioration in Parkinsons, multiple sclerosis (MS), dementia and ALS, and in its role of immune system regulator, can reverse diseases that attack the immune system like Lupus and Arthritis. And is effective with wound healing.

In addition to rebuilding a depressed immune system, GcMAF:

Inhibits angiogenesis – stops blood supply to glucose hungry cells
Activates macrophages – phagocytosis and destruction of glucose hungry cells
Apoptosis – self destruction of glucose hungry cells
Reverts the diseased cell phenotype to normal
Reduces the metastatic potential of human cancer cells in culture.

Increases energy production at the mitochondrial level – ME/CFS
Improves human neuronal metabolic activity through cAMP signaling  – autism, ME/CFS, MS, ALS
Counters toxic effects including cadmium – ME/CFS
It abolishes neuropathic pain due to neuro-oxidative stress (stress due to the anti-cancer drug oxaliplatin) in the lab. (neurodegenerative diseases and autism that have oxidative stress as a pathogenetic mechanism)
It increases neuronal connectivity by promoting differentiation and the formation of dendrites and neuritis (autism and ME/CFS, where there is a lack of connectivity between neurons).

See the 16 research papers we have published, particularly Brescia, and the 60 published by others.

Our first stunning breakthrough research paper of 2014 was made available to the public on 2nd January 2014.
Published in the prestigious scientific journal Frontiers in Neuroscience, we have found the point in the brain which defines whether a child has autism or not. In non autistic children that point is 1ml thick. In autistic children it measures 3.4ml. For the first time in autism’s history, there is now a hard diagnostic tool for autism.

GcMAF and Alzheimers

Overproduction of TNF-alpha interrupts synaptic communications in the brain in Alzheimer’s and Parkinsons disease, GcMAF activated macrophages disable TNF-alpha by occupying its receptors.

We’ve now written four papers on these diseases:

American Journal of Immunology. Volume 9, Issue 3. Pages 78-84.
Therapeutic effects of highly purified de-glycosylated GcMAF in the immunotherapy of patients with chronic diseases.
It covers cancer, autism, chronic fatigue syndrome, Lyme disease, multiple sclerosis, amyotrophic lateral sclerosis.

Italian Journal of Anatomy and Embryology (2013) 118 (Suppl. 2): S143 (P28).
Vitamin D binding protein-derived macrophage activating factor stimulates proliferation and signalling in a human neuronal cell line. Autism, chronic fatigue syndrome, multiple sclerosis and amyotrophic lateral sclerosis

Italian Journal of Anatomy and Embryology (2013) 118 (Suppl. 2): S144.
Treatment and Prevention of Cadmium-induced alterations on human neurons.

American Journal of Immunology. Published the 8th November 2013.
Effects of GcMAF on human neurons and ME/CFS treatment.

Neurodegenerative conditions

Multiple Sclerosis (MS), Acute brain traumas, Psychiatric disorders, Brain aging

Activation of macrophages appears to be essential in repairing central nervous system (CNS) lesions, such as those observed in MS.

In fact, monocyte-derived macrophages provide multi-functional contribution in various neurological conditions, ranging from acute traumas to neurodegenerative disorders.

The diverse functions of macrophages are manifested by induction and resolution of inflammation as well as their involvement in neural tissue regeneration and renewal, matrix remodeling and debris clearance (J Pathol. 2012 Sep 24. doi: 10.1002/path.4106)

These recent advances reveal a dramatic therapeutic opportunity for controlled harnessing of macrophages for repair of the damaged CNS following acute assaults, in neurodegenerative conditions, and in psychiatric disorders.

Therefore, activation of macrophages by GcMAF could prove useful in brain regeneration and repair

 

This leads to the hypothesis that GcMAF would slow the process of brain aging. It has been recently proposed that monocyte-derived cells serving multiple roles within the brain have a long term impact on the functional vulnerability of the brain to environmental, physical, age-related, or disease-related assaults (Neurotoxicology. 2012 Mar;33(2):191-206)

This is very new science, and whereas GcMAF, as a part of all healthy people, won’t do any harm, we have as yet little proof this theoretical science works in practice. We understand drinking 4+ pints of water with silica (eg Volvic Spring water) a day to chelate aluminium, and taking himalayan Rock salt, high doses of the B vitamins, particularly B12, and high doses of vitamins C and E together should also help.

Myalgic Encephalomyelitis, ME, named Chronic Fatigue syndrome, CFS in the USA, is mainly a viral disease.

Some people with CFS have a reaction as their immune system is rebuilt. Participants are therefore advised to start on a low dose, 0.05ml, then 0.05ml on the fourth day, then 0.1ml after 7 more days. After that a normal shot of 0.25ml twice a week. If you have a reaction, stick to 0.05ml for four weeks, then try to increase again.

At the GcMAF Conference 2013 it has become clear that we are now eradicating ME/CFS in 50% of cases, a big improvement on the 30% full recoveries we were making last year. Subsequent data from our own CFS self help group shows another big increase to 70%, as people get further down the track. (June 2014: we now 85% success with 70% of participants)

ME/CFS is brought on by differing circumstances including a weakened immune system coupled with stress. The speed of recovery to normal health depends on the type of ME; variants include phosphate or pesticide poisoning, digestive, mitochondrial, liver or hormone imbalances.

People with ME/CFS have high nagalase and collapsed immune systems, because the viruses are preventing production of their own GcMAF.

We have about 120 ME participants on our GcMAF, many through the four of our 100 doctors who specialise in ME.

Although everyone promises on our gcmaf.eu website to give feedback, only about 15% do, so we have done some chasing up on ME and have just 35 replies. To be fair, we have no way of contacting those participants who went though doctors, and few doctors respond. (But this data below is now superceeded by the GcMAF conference results above.)

If you get worse temporarily that does not means the disease will not eventually be eradicated.

Unfortunately viruses are clever things. In the case of ME it seems they can block the VDR, conceal themselves with biofilms, and when their lives are threatened by an immune system rebuilt by GcMAF, they can arise from their dormant state and go on the attack, which can exhaust you.  To avoid that you should start GcMAF with small, 0.05ml increasing doses,  and reduce the dose if your viruses wake up. But some people simply improve.

Preliminary results from our trial show LDN blocks progress while on GcMAF.

With 8,000 people on it, we now know there are no side effects to our GcMAF itself. When there are side effects, it is the rebuilt immune system that causes them.

GcMAF / ME developments

We have no doubt that GcMAF and the immune system will prove to be the eventual cure for ME, and the GcMAF/ME research that we and other scientists have started will bring that about. 2014 – that has now happened with 70% effectiveness. In clinics we are closer to 100%.

For the meantime, to improve on the above response rates, you need GcMAF, 10,000IU vitamin D a day, zinc, magnesium (Professor Stefania Pacini’s research) and probiotic yoghurt.

Cyder apple vinegar, grape seed extract, Bromelain and Papain may encourage enzymes to devour biofilms. And in ME, exercise sometimes does more damage than good.

If you wish to detox: Emulsified vitamin A, selenium and vitamin E (for the lymphatic system to carry away wastes). Non responders can respond if they take Chlorella with cod liver oil that has correct ratios of vit A to D. This binds to heavy metals and chelates them out and also offers absorption of missing minerals.

Don’t forget to eat plenty of lipids (meat and fish), the food of your immune system and neurological systems. Avoid vegetarian diets.

David Noakes.

Refferences

List of 25 peer-reviewed scientific publications that use our GcMAF – 16 have been produced by Immuno Biotech Ltd.

2011
1. Gc protein-derived macrophage-activating factor (GcMAF) stimulates cAMP formation in human mononuclear cells and inhibits angiogenesis in chick embryo chorionallantoic membrane assay.
Pacini S, Morucci G, Punzi T, Gulisano M, Ruggiero M.
Cancer Immunol Immunother. 2011 Apr;60(4):479-85. doi: 10.1007/s00262-010-0953-7. Epub 2010 Dec 14.

Here it is demonstrated that GcMAF from Immuno Biotech Ltd is as effective as Dr. Yamamoto’s GcMAF in inhibiting angiogenesis, a key event in tumour progression.

2. Effects of Cadmium and vitamin D binding protein-derived macrophage activating factor (DBP-MAF) in human breast cancer cells.
Massimo Gulisano, Tiziana Punzi, Gabriele Morucci, Marco Ruggiero.
It. J. Anat. Embryol. Vol. 116, No 1 (Supplement) 2011.

Here it is demonstrated that GcMAF counteracts the noxious effects of Cadmium, an ubiquitous heavy metal pollutant involved in autism, chronic fatigue syndrome and neurodegenerative diseases.

2012
1. Effects of vitamin D-binding protein-derived macrophage-activating factor on human breast cancer cells.
Pacini S, Punzi T, Morucci G, Gulisano M, Ruggiero M.
Anticancer Res. 2012 Jan;32(1):45-52.

On the effects of GcMAF in human breast cancer cells in vitro. GcMAF reverts the neoplastic phenotype; cancer cells become normal and are deprived of their metastatic potential.

2. Effect of paricalcitol and GcMAF on angiogenesis and human peripheral blood mononuclear cell proliferation and signaling.
Pacini S, Morucci G, Punzi T, Gulisano M, Ruggiero M, Amato M, Aterini S.
J Nephrol. 2012 Jul-Aug;25(4):577-81. doi: 10.5301/jn.5000035.

GcMAF stimulates human monoctyes and the individual responsiveness is dependent upon the vitamin D receptor (VDR) genotype. GcMAF in chronic kidney disease.

3. Cadmium toxicity, with particular regard to myalgic encephalomyelitis/chronic fatigue syndrome; application of transcranial sonography to the study of cadmium-induced neuronal damage.
Massimo Gulisano, Gabriele Morucci, Stefania Pacini, Jacopo Branca and Marco Ruggiero.
Abstr. International Cadmium Symposium 2012, Sassari, Italy, P. 36.

GcMAF counteracts the effects of toxic Cadmium. Relevant for ME/CFS, and the first transcranial sonography paper.

2013
1. Effects of vitamin D3 and paricalcitol on immature cardiomyocytes: a novel role for vitamin d analogs in the prevention of cardiovascular diseases.
Pacini S, Morucci G, Branca JJ, Aterini S, Amato M, Gulisano M, Ruggiero M.
Nutrients. 2013 Jun 7;5(6):2076-92. doi: 10.3390/nu5062076.

GcMAF increases energy production at the mitochondrial level. These results explain the reported increase of energy observed by patients treated with GcMAF for different diseases.

2. A novel role for a major component of the vitamin D axis: vitamin D binding protein-derived macrophage activating factor induces human breast cancer cell apoptosis through stimulation of macrophages.
Thyer L, Ward E, Smith R, Fiore MG, Magherini S, Branca JJ, Morucci G, Gulisano M, Ruggiero M, Pacini S.
Nutrients. 2013 Jul 8;5(7):2577-89. doi: 10.3390/nu5072577.

GcMAF activates macrophages that attack and destroy human breast cancer cells. The molecular assembly and mode of action of GcMAF are elucidated. For the first time an interconnection with the vitamin D receptor (VDR) signalling is presented.

This paper is in the top 5% of all articles ever tracked by Altmetric. The Altmetric score is one measure of the quality and quantity of online attention that this article has received. Altmetric has tracked more than 1.500.000 articles across all journals so far. Compared to these this article has done particularly well and is in the 95th percentile.

http://www.altmetric.com/details.php?domain=www.mdpi.com&citation_id=1633677#

3. Therapeutic effects of highly purified de-glycosylated GcMAF in the immunotherapy of patients with chronic diseases.
Lynda Thyer, Emma Ward, Rodney Smith, Jacopo J.V. Branca, Gabriele Morucci, Massimo Gulisano, David Noakes and Stefania Pacini. DOI : 10.3844/ajisp.2013.78.84.
American Journal of Immunology. Volume 9, Issue 3. Pages 78-84.

http://www.thescipub.com/abstract/10.3844/ajisp.2013.78.84 – the .PDF is on the right.

On the therapeutic effects of GcMAF in patients with cancer, autism, chronic fatigue syndrome, Lyme disease, multiple sclerosis, amyotrophic lateral sclerosis. This is the first report on the therapeutic effects of GcMAF in patients with these dreadful neurological diseases.

4. Gc protein-derived macrophage-activating factor decreases α-N-acetylgalactosaminidase levels in advanced cancer patients.
Thyer L, Ward E, Smith R, Branca JJ, Morucci G, Gulisano M, Noakes D, Eslinger R, Pacini S. OncoImmunology 2013; 2:e25769; http://dx.doi.org/10.4161/onci.25769.

On the therapeutic effects of GcMAF in 20 patients with advanced cancer defined as incurable. Clinical cases of breast, prostate, bladder, ovarian, colon, tongue, larynx, head and neck carcinomas, lymphomas and oligodedroglioma.

This paper has been awarded the front cover of the August issue of the Journal OncoImmunology.

5. Initial Observations of elevated Alpha-n-Acetylgalactosaminidase Activity Associated with Autism and Observed Reductions from GC Protein—Macrophage Activating Factor Injections. James Jeffrey Bradstreet, emar Vogelaar and Lynda Thyer.
Autism Insights 2012:4 31–38. doi: 10.4137/AUI.S10485.

On the therapeutic effects of GcMAF in autism. Autism is eradicated in a significant percentage of cases. About 85% of subjects show improvement following GcMAF treatment.

6. Study of aminoacidic sequences of vitamin D binding proteins involved in macrophage activation.
Fiore MG, Magherini S, Gulisano M, Pacini S and Ruggiero M (2013).
Front. Immunol. Conference Abstract: 15th International Congress of Immunology (ICI). doi: 10.3389/conf.fimmu.2013.02.01124.

On the physiological molecular assembly of GcMAF.

7. Multifaceted immunotherapeutic effects of vitamin D-binding protein-derived macrophage activating factor (GcMAF) on human breast cancer and neuroblastoma cells.
Ruggiero M, Pacini S, Morucci G, Branca J, Ward E, Smith RJ, Thyer L and Gulisano M (2013).
Front. Immunol. Conference Abstract: 15th International Congress of Immunology (ICI). doi: 10.3389/conf.fimmu.2013.02.00221.

On the multifaceted effects of GcMAF in human breast cancer cells and human neuroblastoma (a brain tumour) cells. Here it is demonstrated that when GcMAF is prepared according to its molecular configuration, it is 100 fold more effective than “regular” GcMAF in destroying human cancer cells.

8. Effects of vitamin D binding protein-derived macrophage activating factor on human neuroblastoma cells and predicted molecular interaction with the vitamin D receptor.
M. Ruggiero, M.G. Fiore, S. Magherini, G. Morucci, J.J.V. Branca, M. Gulisano, L. Thyer, S. Pacini. Abstr.
The European Cancer Congress 2013. P91-596. Amsterdam, 2013.

On the molecular events responsible for the anticancer effects of GcMAF.

9. Vitamin D binding protein-derived macrophage activating factor
stimulates proliferation and signalling in a human neuronal cell line.
Morucci G, Fiore MG, Magherini S, Branca JJV, Gulisano M, Thyer L, Ruggiero M and Pacini S.
Italian Journal of Anatomy and Embryology (2013) 118 (Suppl. 2): S143 (P28).

The effects of GcMAF on human neurons explain its therapeutic effects in autism, chronic fatigue syndrome, multiple sclerosis and amyotrophic lateral sclerosis.

10. Treatment and Prevention of Cadmium-induced alterations on human neurons.
Morucci G, Branca JJV, Ruggiero M, Gulisano M and Pacini S. (P29).
Italian Journal of Anatomy and Embryology (2013) 118 (Suppl. 2): S144.

GcMAF has a neuro-protective effect against heavy metal-induced neuronal damage. Implications for autism and chronic fatigue syndrome treatment.

11. A molecular model of the interaction between vitamin D binding protein-derived macrophage activating factor and vitamin D receptor.
Fiore MG, Magherini S, Morucci G, Branca JJV, Pacini S, Gulisano M and Ruggiero M. (P50). Italian Journal of Anatomy and Embryology (2013) 118 (Suppl. 2): S89.

On the physiological molecular assembly of GcMAF. Its interaction with the VDR signalling is elucidated. The molecular mechanism explaining why GcMAF has so many biological effects with therapeutic implications.

12. Alpha‐N‐acetylgalactosaminidase levels in cancer patients are affected by Vitamin D binding protein‐derived macrophage activating factor.
Gulisano M, Pacini S, Thyer L, Morucci G, Branca JJV, Smith R, Wards E and Noakes D. (P85). Italian Journal of Anatomy and Embryology (2013) 118 (Suppl. 2): S104.

GcMAF has a significant therapeutic effect in 20 patients with advanced cancer. These results are presented at the 67th National Congress of the Italian Society of Anatomy and Histology. This is one of the oldest and most respected European Scientific Societies, founded in 1929

13. The immune stimulant properties of vitamin D binding protein-derived macrophage activating factor can minimise morbidity in gynaecological cancers. Smith R.
Abstr. British Gynaecological Cancer Society and Irish Gynaecological Cancer Society annual meeting. P027-92, 2013. Belfast, Ireland.

14. Molecular interaction of vitamin D binding protein macrophage activating factor with vitamin D receptor; a new perspective in endometrial cancer. Thyer L.
Abstr. British Gynaecological Cancer Society and Irish Gynaecological Cancer Society annual meeting. P136-201, 2013. Belfast, Ireland.

15. Immunotherapeutic Effects of Vitamin D-binding Protein-derived Macrophage Activating Factor (GcMAF) on Human Breast Cancer Cells.
Ruggiero M, Pacini S, Ward E, Smith RJ, Thyer L, Gulisano M. Multifaceted Abstr. 5th Immunotherapeutic and Immunomonitoring Conference 2013, San Diego, CA, USA.

On the effects of GcMAF on human breast cancer cells.

16. On the effects of Vitamin D-binding protein-derived macrophage activating factor (GcMAF) on human breast cancer and neuroblastoma cells.
Ward E, Smith RJ, Thyer L, and Noakes D.
Abstr. 3rd Immunotherapeutic and Immunomonitoring Conference 2013, Krakow, Poland.

17. Role of Vitamin D Binding Protein-derived Macrophage Activating Factor (GcMAF) in the immunotherapy of cancer.
Lynda Thyer; Rod Smith; Emma Wards; David Noakes.
Conference proceedings, II Anticancer drugs 2013. O19-27 Stockholm, Sweden.

18. Group component protein-derived macrophage activating factor stimulates macrophages that induce human breast cancer cell apoptosis.
M. Ruggiero, L. Thyer, E. Ward, R. Smith, J.J.V. Branca, M. Gulisano, G. Morucci, S. Pacini.
Intl. J. Gynecol. Cancer. ECCO meeting abstr. 2013. Ovarian and Breast Cancer. P. 140.

19. Vitamin D binding protein-derived macrophage activating factor inhibits human breast cancer cell proliferation and decreases alpha-N-acetyl galactosaminidase in breast cancer patiens
L. Thyer, G. Morucci, J.J.V. Branca, E. Ward, R. Smith, D. Noakes
Intl. J. Gynecol. Cancer. ECCO meeting abstr. 2013. Ovarian and Breast Cancer. P. 145.

20. American Journal of Immunology. Effects of GcMAF on human neurons and ME/CFS treatment. Published the 8th November.

GcMAF is able to increase the viability and the metabolism of human neurons, and, most important, to induce neurons to establish contact with each other. As it is well known in the field of neurosciences, a decreased connectivity among neuronal circuits is at the basis of most, if not all, neurological and neurodevelopmental disorders. The paper also explains why GcMAF combats pain.

http://thescipub.com/abstract/10.3844/ajisp.2013.120.129